Cabozantinib, Immunotherapy Combo Shows Promise Against Genital and Urinary Cancer – Immuno-Oncology News
Immuno-Oncology News |
Cabozantinib, Immunotherapy Combo Shows Promise Against Genital and Urinary Cancer
Immuno-Oncology News Combining cabozantinib with either Opdivo (nivolumab) or Opdivo plus Yervoy (ipilimumab) shows promise as a treatment for refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors, according to results of a Phase 1 trial. The … |
